Nodal marginal zone lymphoma

Luca Arcaini, Andreas Viardot

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The nodal marginal zone lymphoma (NMZL) is a rare indolent lymphoma within the group of marginal zone lymphomas. Although recognized as a distinct entity in the lymphoma classifications since 1994 (REAL and WHO), the differential diagnosis with other lymphomas is still imprecise and clinically requires the exclusion of extranodal or splenic involvement. With regard to treatment, prospective data are limited. Often, the guidelines refer to other indolent lymphomas like follicular lymphoma. Novel drugs were developed parallel to follicular lymphoma or other MZLs, particularly lenalidomide, ibrutinib, or PI3K inhibitors. In the last years, there is an increasing amount of molecular data underlining that NMZL is a separate entity requiring more specific treatments.

Original languageEnglish
Title of host publicationHematologic Malignancies
PublisherSpringer Science and Business Media Deutschland GmbH
Pages117-125
Number of pages9
DOIs
Publication statusPublished - 2021

Publication series

NameHematologic Malignancies
ISSN (Print)2197-9766
ISSN (Electronic)2197-9774

Keywords

  • Chemoimmunotherapy
  • Ibrutinib
  • Indolent lymphoma
  • Lenalidomide
  • Nodal marginal zone lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Nodal marginal zone lymphoma'. Together they form a unique fingerprint.

Cite this